Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 15/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.55 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13239371 | 0.99 | PTGER1 (0.84) | PTGER1CYP1A2CYP2C9TBXA2RPTGS1 | |
| SCHEMBL13239373 | 0.95 | PTGER1 (0.84) | PTGER1CYP1A2CYP2C9TBXA2RPTGS1 | |
| SCHEMBL2953564 | 0.91 | PTGER1 (1.00) | PTGER1CYP1A2CYP2C9TBXA2RPTGS1 | |
| SCHEMBL2953241 | 0.90 | PTGER1 (1.00) | PTGER1CYP1A2CYP2C9TBXA2RPTGS1 | |
| SCHEMBL2950174 | 0.87 | PTGER1 (0.77) | PTGER1CYP1A2CYP2C9 | |
| SCHEMBL2963288 | 0.86 | PTGER1 (0.77) | PTGER1CYP1A2CYP2C9 | |
| SCHEMBL2960857 | 0.85 | PTGER1 (1.00) | PTGER1CYP1A2CYP2C9TBXA2RPTGS1 | |
| SCHEMBL13239375 | 0.84 | PTGER1 (0.64) | PTGER1CYP1A2CYP2C9TBXA2RPTGS1 | |
| SCHEMBL2958946 | 0.82 | PTGER1 (0.76) | PTGER1CYP1A2CYP2C9 | |
| SCHEMBL14098735 | 0.80 | PTGER1 (0.60) | PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759369-B2 | Pyridine compounds for the treatment of prostaglandin mediated diseases | GLAXO GROUP LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| US-7759369-B2 | Pyridine compounds for the treatment of prostaglandin mediated diseases | GLAXO GROUP LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| US-20100137378-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | GLAXO GROUP LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| EP-2053042-A1 | Pyridine compounds for the treatment of prostaglandin mediated diseases | Glaxo Group Limited (GB) | 2009-04-29 | — | — | EP | disclosed |
| EP-1833795-B1 | PYRIDINE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20080249138-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | MARTIN PAUL GIBLIN GERARD | 2008-10-09 | — | — | US | disclosed |
| US-20080249138-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | MARTIN PAUL GIBLIN GERARD | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137378-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | PTGER1, PTGDR, PTGER2 | PTGER1 1/4885CYP1A2 241/4885CYP2C9 122/4885 |
| US-20080249138-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | PTGER1, PTGDR, PTGER4 | PTGER1 1/4885CYP1A2 140/4885CYP2C9 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.